Model‐informed drug development of voxelotor in sickle cell disease: Exposure‐response analysis to support dosing and confirm mechanism of action

por Green, Michelle L., Savic, Radojka M., Tonda, Margaret, Jorga, Karin, Washington, Carla B.
Publicado 2022

The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease

por Minniti, Caterina P., Knight‐Madden, Jennifer, Tonda, Margaret, Gray, Sarah, Lehrer‐Graiwer, Joshua, Biemond, Bart J.
Publicado 2021

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease

por Telfer, Paul, Agodoa, Irene, Fox, Kathleen M., Burke, Laurie, Mant, Timothy, Jurek, Marzena, Tonda, Margaret, Lehrer-Graiwer, Josh
Publicado 2018